Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.44 |
| ▸ | CNR1 | P21554 | 5/20 | 0.44 |
| ▸ | JAK1 | P23458 | 6/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284561 | 0.94 | CNR2 (0.52) | CNR2CNR1JAK1JAK2LMNA | |
| SCHEMBL16254983 | 0.94 | CNR2 (0.52) | CNR2CNR1JAK1JAK2LMNA | |
| SCHEMBL9892061 | 0.87 | CNR2 (0.51) | CNR2CNR1JAK1JAK2LMNA | |
| SCHEMBL9892784 | 0.85 | CNR2 (0.41) | CNR2CNR1JAK1JAK2LMNA | |
| SCHEMBL2123122 | 0.75 | ALDH1A1 (0.60) | CNR2CNR1LMNAMAPT | |
| SCHEMBL20458159 | 0.75 | ALDH1A1 (0.60) | CNR2CNR1LMNAMAPT | |
| SCHEMBL3790780 | 0.75 | CNR2 (0.51) | CNR2CNR1JAK1JAK2LMNA | |
| SCHEMBL13256989 | 0.75 | CNR2 (0.51) | CNR2CNR1JAK1JAK2LMNA | |
| SCHEMBL9892924 | 0.74 | MEN1 (0.48) | LMNAMAPT | |
| SCHEMBL9892870 | 0.73 | KHK (0.46) | JAK1JAK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885JAK1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.